复星医药肝素钠注射液药品注册申请获受理

Core Viewpoint - Fosun Pharma's subsidiary, Suzhou Er Ye Pharmaceutical Co., Ltd., has received acceptance for its drug registration application for Heparin Sodium Injection from the National Medical Products Administration, indicating a significant step in expanding its product portfolio in the anticoagulant market [1] Group 1 - The Heparin Sodium Injection is intended for the prevention and treatment of venous thrombosis and pulmonary embolism, as well as for patients at risk of thromboembolic diseases due to major surgeries or other reasons [1] - The drug will also be used for the treatment of atrial fibrillation with embolism, acute and chronic consumptive coagulopathy (disseminated intravascular coagulation), and to prevent coagulation during arterial and cardiac surgeries [1] - Additionally, it serves as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis [1]